Search Results
Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer
Dr. Rugo on Ongoing Trials in HER2+ Breast Cancer
Dr. Rugo on the Impact of Margetuximab Based on CD16A Fc Receptors in HER2+ Breast Cancer
SOPHIA Trial in R/R HER2+ mBC
At ASCO 2019, Dr. Hope Rugo presents on results of the SOPHIA breast cancer study
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior ant...
Margetuximab Plus Chemotherapy in HER2+ Breast Cancer
Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trials
Debu Tripathy, MD, elaborates on the SOPHIA trial in HER+ metastatic breast cancer
Dr. Pegram on Margetuximab Plus Chemo in HER2+ Breast Cancer
HER2CLIMB and NALA Trials: R/R HER2+ mBC
Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer
